Female hormones are thought to be of importance in the aetiology of migraine, which is more common in women than in men. Little attention has been paid to androgens. This study investigates the associations between migraine and serum levels of androgens in postmenopausal women not taking oestrogens. A case-control study was carried out among women participating in a mammography screening program. A neurologist clinically assessed the participants. Headache criteria proposed by the International Headache Society were used. Each of the 15 women with migraine was matched to three controls by time since menopause and by body mass index. Serum levels of androstenedione and total testosterone were measured by radioimmunoassays. Free testosterone was calculated from total testosterone, immunoassayed sex hormone-binding globulin and albumin. The meanpS.D. serum level of androstenedione was 2.7p1.1 nmol/l and 3.4p1.9 nmol/l in cases and controls respectively. The mean serum level of testosterone was 0.8p0.4 nmol/l and 1.0p0.5 nmol/l in cases and controls respectively. The mean serum level of free testosterone was 12.5p8.5 pmol/l and 14.0p7.9 pmol/l in cases and controls respectively. Conditional logistic regression analysis was used to test for differences in serum levels of androstenedione, total testosterone and free testosterone between cases and controls. No statistically significant differences were found. To conclude, there was no evidence in this study that differences within normal levels of androgens play an important role in the aetiology of migraine in postmenopausal women not taking oestrogens.
INTRODUCTION
Migraine is a prevalent neurovascular disorder affecting a larger proportion of women than men [1] . Many authors believe that female sex hormones are of importance in migraine [2] [3] [4] [5] . The female-to-male prevalence ratio peaks at around the age of 40 years [6] and declines thereafter. In old people, migraine is still somewhat more common in women than in men [1, 6] .
Between one-fourth and two-thirds of all patients report that their migraine attacks are triggered by menstruation [7] [8] [9] . Early studies by Somerville [10] indicated that fluctuations in the concentration of blood oestrogens premenstrually are the biological basis for menstruation as a migraine trigger. The impact of Key words : androstenedione, menopause, migraine, testosterone.
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menopause and hormone replacement therapy on migraine seems complex [11] .
Migraine research has focused on female sexual hormones and their effects, whereas little attention has been paid to androgens [3] . The results of some open trials indicate that testosterone may prevent migraine attacks [12, 13] . Epstein et al. [14] reported that the concentrations of plasma total testosterone were normal in eight migraine patients. Dennerstein et al. [15] studied 32 women in surgical menopause who ceased to take oestrogen for a fortnight. During this period, the levels of total testosterone were higher in women with headaches than in those without headaches.
We argued that an association between migraine and androgens might be easier to detect in women with low levels of oestrogens than in menstruating women or in women taking oestrogens. In the present study, we tested the hypothesis that circulating androgens, i.e. androstenedione, testosterone and bioavailable testosterone [16] , are important in migraine in postmenopausal women not using oestrogens.
METHODS

Study population
The study population has been characterized in greater detail previously [17] . All women aged 40-74 years in O = sthammar, a community in the middle of Sweden, are invited regularly to a mammography screening program. The attendance rate at the mammography screening program was high : approx. 79 % of all invited women went to the local mammography unit, 7 % went to the central mammography unit and 14 % did not respond to the invitation.
Nine hundred and ninety-six women were invited to attend the mammography screening program. Of these, 158 women did not attend the mammography unit for screening. Of the 838 women who did attend, 728 ambulant women (86.9 % of the 838 women) participated in our investigation, which was conducted from November 1997 to October 1998.
Among the 728 participating women, 301 women were in natural menopause. Of these women, 73 used hormone replacement therapy, 21 used oestrogens for vaginal application and 48 women declined to give a blood sample. This left 159 women for the study.
Study design
Sixteen of the 159 eligible women suffered from migraine. For each case (woman with migraine) we matched three controls (women without migraine) by time since menopause (within p2 years for women who had undergone menopause less than 15 years previously and within p5 years for women who had their menopause more than 15 years previously) and body mass index (BMI) (within p2.5 kg : m −# ). It was not possible to find any control for one woman who had a BMI of 38 and who had undergone menopause very recently. Thus, there were 15 cases and 45 controls. We matched cases and controls for time since menopause and BMI, because these factors may influence the concentrations of circulating androstenedione, sex hormone-binding globulin (SHBG) and testosterone [18, 19] .
Interview, measures and definitions
A board-certified neurologist interviewed the participants. Physical and neurological examinations were not performed. The interview structure was based on the headache criteria proposed by the International Headache Society [20] . Women with migraine in this study had migraine without aura (n l 13), i.e. migraine without any preceding neurological symptom, or migrainous disorder (n l 2, one criterion for migraine without aura was missing). All women with migraine experienced inhibition (moderate disability) or prohibition (severe disability) of daily activities during migraine attacks. All participants had experienced at least one migraine attack during the previous year.
Data on menstrual status and current use of hormone replacement therapy (ATC codes, G03C, G03D, and G03F) were obtained through direct interview. Postmenopausal women were in natural (non-surgical) menopause. They had had their last periods at least 1 year prior to the study. An assistant measured the height and weight of the participants.
The study was carried out in accordance with the Declaration of Helsinki (1989) of the World Medical Association. All women gave their informed consent for participation and the Ethics Committee of the Medical Faculty, University of Uppsala, approved the study (number 97307).
Analyses of sex hormones
Blood samples were drawn from the cubital vein between 09:00 and 17:00 hours. Participants were sitting when samples were taken. The time the sample was taken was recorded. After 30 to 60 min, serum was separated from cells by centrifugation at 1360 g for 10 min and then immediately stored at approx. k18 mC. Within 1 to 3 months, the samples were delivered to our laboratory where they were stored at k70 mC until analysis in December 2000.
SHBG and albumin were measured for use in the calculations of free testosterone [16] . Oestradiol was measured to confirm the menopausal status of the participants and for use in the analysis of confounding effects.
Androstenedione was measured using a radioimmunoassay (Androstenedione DSL-4200 ; Diagnostic Systems Laboratories, Webster, TX, U.S.A.). The inter-and intraassay variation coefficient for androstenedione was less than 8 % for the whole concentration range. The detection limit was 0.07 nmol\l and the reference values were 1.6-9.4 nmol\l. Total testosterone was measured using a solid-phase radioimmunoassay (Coat-A-Count total testosterone ; Diagnostic Products Corporation, Los Angeles, CA, U.S.A.). The inter-and intra-assay variation coefficient for Coat-A-Count total testosterone was less than 10 % for the upper concentration range, and between 15 and 20 % for the lower concentration range. The detection limit was set to 0.5 nmol\l and the reference values from not detectable to 2.9 nmol\l. Oestradiol and SHBG were measured using a time-resolved fluoroimmunoasssay (AutoDELFIA TH oestradiol and AutoDELFIA TH SHBG ; Wallac Sverige AB, Upplands Va$ sby, Sweden). The inter-and intraassay variation coefficient for AutoDELFIA TH SHBG was less than 5 % for the whole concentration range. The detection limit was 0.5 nmol\l and the reference values were 25-130 mmol\l. The inter-and intra-assay variation coefficient for AutoDELFIA TH oestradiol was less than 10 % for the whole concentration range. The detection limit was 0.05 nmol\l and the reference values were 20-70 pmol\l. Albumin was measured using a colourimetric assay end-point method (Albumin Plus ; Roche).
The reference values were 37-48 g\l. There were no reference values for the calculated values of free testosterone.
Data analysis
In a first step, conditional logistic regression analysis was used to test for differences between the 15 cases and 45 controls. This constituted the main analysis (intent-toanalyse analysis, which is analogous to an intent-to-treat analysis). In a second step, the data were re-evaluated after exclusion of participants with very high or undetectable levels of sex hormones (see the Results section). Undetectable values of testosterone were set at 0.25 nmol\l. We also tested for the confounding effect of the continuous variables ' time at blood sampling ' and ' concentration of oestradiol ' by introducing one variable at a time in each conditional logistic regression analysis that was performed in the first analytical step. The statistical program package JMP (version 4.0) was used. P-values of less than 0.05 were considered significant. All tests were two-sided.
This study was part of a larger epidemiological study. Therefore, power calculations for the present study could not be done beforehand. The upper normal level of total testosterone is 2.9 nmol\l. If we consider a difference of 0.5 nmol\l in total testosterone to be clinically significant, and assume a standard deviation of 0.5 nmol\l, the power to detect this difference on the 5 % significance level, the power of this study can be calculated to be larger than 90 % [21] .
RESULTS
Characteristics of cases and controls
There was no statistically significant difference between cases and controls with regard to age (range, 49-74 years), time since menopause (range, 1-31 years), BMI (range, 20.7-37.5 kg : m −# ), time at blood sampling (range, between 09:00 and 17:00 hours), serum concentration of oestradiol (range, 30-313 pmol\l), serum concentration of SHBG (range, 14-194 mmol\l), or serum concentration of albumin (range, 40-55 g\l) ( Table 1 , conditional logistic regression analysis). Table 2 shows the mean values and the corresponding standard deviations of androstenedione (range, 0.9-8.2 nmol\l), total testosterone (range, not detectable-2.9 nmol\l) and free testosterone (range, not detectable-33.7 pmol\l) in women with and without migraine. Undetectable values of testosterone were set at 0.25 nmol\l. The same value was used in the calculations of free testosterone. There were no statistically significant differences in the levels of sex hormones between cases and controls. The level of testosterone was lower than the detection level in five controls and two cases.
Serum levels of androgens
In the second step of the analysis, one woman with a high level of oestradiol (313 pmol\l) and her controls were excluded. The two cases with undetectable levels of testosterone and their controls and the five controls with undetectable levels of testosterone were also excluded. The only woman who had an elevated level of SHBG (194 mmol\l) was in this group. This left 12 cases and 32 controls for the re-analysis of the data. There was at least one control for every case in the re-analysis. The associations between migraine and the sex hormones in Table 2 remained statistically insignificant.
Analysis of confounding effects
Controlling for time at blood sampling, the P-values for androstenedione, total testosterone and free testosterone were 0.10, 0.07 and 0.44 respectively. Controlling for oestradiol, the P-values for androstenedione, total tes-tosterone and free testosterone were 0.16, 0.07 and 0.44 respectively.
DISCUSSION
In this case-control study of postmenopausal women not taking oestrogen-containing medications, there were small and statistically non-significant differences in serum levels of androstenedione, testosterone and calculated free testosterone between women with and without migraine.
To the best of our knowledge, this is the first study focusing on androgens and migraine in postmenopausal women. Previous studies [14, 15] have measured total testosterone. We calculated the free fraction from the levels of total testosterone, SHBG and albumin [16] . This method yields values very close to those obtained by the ' golden standard ', i.e. equilibrium dialysis, in postmenopausal women [16] . Free testosterone probably reflects biologically active testosterone better than total testosterone does [22] . In this study, androstenedione was included, because it may be as important as testosterone regarding androgenic features in women [23] .
The criteria for migraine proposed by the International Headache Criteria were used, although they were slightly modified ; all women had experienced some reduction in their daily activities. Thirteen cases had migraine without aura and two cases had migrainous disorder, i.e. one criterion was missing. This is unlikely to effect the main conclusion of the study. We did not focus on women with aura, because this subgroup of migraine is less associated with hormonal factors [24, 25] and less prevalent than migraine without aura. Previous studies have used different criteria [14] or have not separated migraines from other headaches in the analysis of the association with androgens [15] .
The present study was designed as a case-control study within a population-based sample, which has been shown to be representative of the corresponding age and sex segment of a community in Sweden [17] . This makes selection bias less likely than in previous studies of patient samples. Participants were interviewed by a board-certified neurologist, which is of special importance in association studies.
There were several confounders with the potency to threaten the validity of this study. Confounding by differences in time since menopause and by BMI was controlled through the study design. There were small and statistically non-significant differences with regard to age, time at blood sampling, serum concentration of oestradiol, SHBG and albumin. We formally tested whether oestradiol and time at blood sampling confounded the relationship between the androgens and migraine, but they did not do so. Albumin and SHBG were included in the calculations of free testosterone.
Other potential biases include unknown biases and biases such as active liver and thyroid disease. The study did not control for these biases. However, we believe that we dealt appropriately with the most important confounders.
In the re-analysis of the data, one woman with a high level of oestradiol and her controls were excluded. We rechecked whether she had been misclassified according to the use of oestrogens or menopausal status, but the original data did not reveal misclassification. She may have used non-prescription drugs containing oestrogens. Further, the two cases with undetectable levels of testosterone and their controls, and the five controls with undetectable levels of testosterone, were also excluded. This manoeuvre did not change the results of the study, which means that the results were insensitive to misclassification of cases and testosterone values in a range where the coefficient of variation is somewhat high.
The power of this study to detect a small difference of total testosterone between cases and controls was larger than 90 %. The highest concentration of total testosterone, 2.9 nmol\l, was below the upper reference limit, 3.0 nmol\l. This indicates that differences within the reference range of total testosterone are unlikely to be of importance in migraine in postmenopausal women. However, it cannot be excluded that higher levels of testosterone or androstenedione (for example from substitution) have effects on migraine in postmenopausal women.
To conclude, there was no evidence in the present study that differences within normal levels of androgens play an important role in the aetiology of migraine in postmenopausal women not taking oestrogens.
